** Shares of Emergent BioSolutions EBS.N fall 12.5% to $5.98 in extended trading, the lowest since September
** Company reported a decline in its fourth-quarter revenue, which stood at $194.7 million, down from $276.6 million a year ago
** On an adjusted basis, company reported EPS of 5 cents, vs a loss of 77 cents previous year
** Company is moving forward with turnaround activities, a critical phase in its multi-year transformation plan - EBS
** Company's shares up 298.3% in 2024
(Reporting by Kritika Lamba in Bengaluru)
((Kritika.Lamba@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。